Orforglipron CAS 2212020-52-3

 

What is Orforglipron?

Orforglipron (CAS 2212020-52-3) is a first-in-class, small-molecule, oral GLP-1 receptor agonist currently under clinical research for obesity management, weight loss, and type 2 diabetes.
Unlike traditional peptide-based GLP-1 analogs such as Semaglutide or Tirzepatide, Orforglipron is non-peptidic-making it more stable, easier to formulate, and suitable for oral delivery without injection.

This innovation represents a major advancement in metabolic and obesity research, enabling scientists to explore new pathways of appetite regulation, energy expenditure, and glucose homeostasis.

 

 

For research and development use, Orforglipron has demonstrated potential in:

• Weight-Loss Studies – Promotes satiety and reduces caloric intake via GLP-1 pathway activation.
• Metabolic Regulation – Improves glucose tolerance and insulin sensitivity in preclinical models.
• Energy Balance Research – Enhances energy expenditure and lipid metabolism.
• Appetite Control Mechanisms – Modulates hypothalamic signaling related to hunger and satiety.
• Oral Formulation Studies – Ideal model compound for evaluating oral GLP-1 analog bioavailability and stability.

 

 

 

• Chemical Name: Orforglipron
• CAS Number: 2212020-52-3
• Molecular Formula: C₂₁H₂₃N₅O₃
• Molecular Weight: ~393.44 g/mol
• Purity: ≥98% (HPLC verified)
• Form: White or off-white powder
• Solubility: Soluble in DMSO, ethanol, and methanol

 

 

Orforglipron is a selective GLP-1 receptor agonist, binding to the receptor and mimicking the activity of natural GLP-1 (glucagon-like peptide-1).

• This receptor activation triggers downstream signaling that.
• Enhances insulin secretion in response to glucose
• Suppresses glucagon release
• Slows gastric emptying, leading to prolonged satiety
• Decreases appetite and caloric intake

Unlike peptide GLP-1 drugs, Orforglipron is non-degradable by digestive enzymes, allowing oral dosing and consistent receptor activation.

 

 

Compound	Type	Administration	Key Benefit	Notes
Orforglipron	Non-peptide GLP-1 agonist	Oral	Stable, convenient, cost-efficient	New generation
Semaglutide	Peptide GLP-1 agonist	Injection or oral	Potent, clinically proven	Requires stabilization
Tirzepatide	Dual GIP/GLP-1 peptide	Injection	Dual receptor activity	Injectable only
Liraglutide	Peptide GLP-1 agonist	Injection	Long-acting peptide	Less oral stability

Orforglipron stands out as a non-peptidic oral molecule, potentially transforming obesity and diabetes research through improved delivery and metabolic durability.

 

 

Storage Temperature: –20 °C (long term)

Protect From: Light, moisture, and heat

Shelf Life: ≥3 years under proper storage

Reconstitution: Dissolve in DMSO or ethanol for research use

Note: For laboratory research only. Not approved for human or veterinary use.

 

 

Handle with standard laboratory PPE (gloves, goggles, lab coat).

Avoid inhalation, ingestion, or contact with skin.

Dispose of according to institutional biosafety guidelines.

 

 

Q1: What makes Orforglipron unique?
A: It's the first orally active, non-peptide GLP-1 receptor agonist, eliminating the need for injections and improving formulation versatility.

Q2: How does it differ from Semaglutide or Tirzepatide?
A: Orforglipron is small-molecule, not peptide-based, giving it higher chemical stability and oral bioavailability.

Q3: Can Orforglipron be used with other metabolic agents?
A: Research studies often combine GLP-1 agonists with AMPK activators or SGLT2 inhibitors to explore synergistic metabolic effects.

Q4: Is Orforglipron available in bulk?
A: Yes - we supply bulk and small-quantity Orforglipron for R&D applications worldwide, with full COA and MSDS documentation.

 

 

Orforglipron (CAS 2212020-52-3) represents the future of GLP-1 agonist research - a small, stable, oral compound offering insight into fat loss, appetite control, and metabolic regulation.
For laboratories investigating non-peptide metabolic modulators, Orforglipron is an ideal choice due to its oral activity, stability, and GLP-1 receptor specificity.

 

 

High Purity (≥98%) verified by HPLC and MS

COA & MSDS Provided with every batch

Global Shipping with temperature-controlled packaging

Bulk & Custom Quantities available

Expert Technical Support for metabolic and GLP-1 pathway research

Competitive Pricing for universities, biotech, and R&D institutions

 

 

Orforglipron, Orforglipron peptide, Orforglipron CAS 2212020-52-3, buy Orforglipron, Orforglipron powder for sale, Orforglipron supplier, GLP-1 receptor agonist, non-peptidic GLP-1, oral GLP-1 agonist, Orforglipron metabolic research, Orforglipron weight-loss peptide, Orforglipron obesity research.

 

 

Buy Orforglipron (CAS 2212020-52-3) – a next-generation oral GLP-1 receptor agonist for metabolic and obesity research. High-purity non-peptide compound for advanced weight-management studies.

 

 

 

 

 

 

 

Hot Tags: orforglipron cas 2212020-52-3, China orforglipron cas 2212020-52-3 manufacturers, suppliers, factory, PT 141 for sexual enhancement, Atosiban CAS 90779 69 4, fmoc ile oh cas 71989 23 6, kisspeptin 54 human cas 374683 24 6, Atosiban oxytocin receptor peptide, Kisspeptin 10 for hormone regulation